ClinicalTrials.gg
CompletedNCT02165345Updated Feb 23, 2022

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

A Phase 1 interventional study of Tocilizumab in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 31 sites in 12 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
4th of 21
82 · median 52
Started
2014
the only one that year
Phase 1
4 of 21
none open now
Registered
17th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 1, and was the 17th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with polyarticular-course and systemic juvenile idiopathic arthritis (pJIA and sJIA). Participants from the 2 JIGSAW studies will continue to receive 162 milligrams (mg) of SC tocilizumab with treatment schedule according to arthritis subtype and body weight. Participants will receive the treatment until commercial availability of the drug or for a maximum of 5 years, whichever is earlier.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of either of the JIGSAW studies, study WA28117 (for participants with pJIA) or study WA28118 (for participants with sJIA)
  • Adequate disease control with the use of SC tocilizumab(TCZ)(comparable to the use of IV TCZ, if received prior to enrollment in the JIGSAW study), per clinical judgment of the investigator
  • For participants of : agreement to remain abstinent or use of effective as defined by the study protocol

Exclusion criteria

Exclusion Criteria:

  • Prior discontinuation of SC tocilizumab because of inadequate clinical response during participation in a JIGSAW study
  • Poorly controlled disease (in opinion of treating physician) despite treatment with SC tocilizumab in the JIGSAW study
  • Prior discontinuation of intravenous tocilizumab because of inadequate clinical response or safety events (including )
  • Therapy with biologic agents (except tocilizumab) in the period between completion of the JIGSAW study and screening for the current study
  • Concurrent treatment with disease-modifying anti-rheumatic drugs (DMARDs) (including methotrexate), nonsteroidal anti-inflammatory drugs (NSAIDs), and oral is permitted at the discretion of the investigator
  • Use of live or attenuated vaccines and , such as cyclosporine and cyclophosphamide
  • Any significant concurrent medical or surgical conditions or findings that would jeopardize the participant's safety or ability to complete the study, including but not limited to disease of the nervous, renal, hepatic, cardiac, pulmonary, gastric, or endocrine system or any infection
  • History of alcohol, drug, or chemical abuse within 6 months prior to screening
  • History of atypical tuberculosis (TB) or active TB requiring treatment within 2 years prior to screening
  • Known infection or other acquired forms of immune compromise or inborn conditions characterized by a compromised immune system
  • Clinical signs or symptoms of acute or chronic viral hepatitis or chronic hepatitis arising since enrollment in the JIGSAW study
  • History of concurrent serious gastrointestinal disorders, such as ulcer or inflammatory bowel disease, Crohn's disease, ulcerative colitis, or other symptomatic lower gastrointestinal conditions
  • History of or current cancer or lymphoma
  • Uncontrolled diabetes mellitus with elevated glycosylated (), defined with the use of age-specific standards
  • Any abnormal laboratory values, an elevation of hepatic transaminases ([ [AST] or alanine aminotransferase [ALT]), lowering of , or thrombocytopenia attributed to tocilizumab use by investigator at screening, the participant may be enrolled; however, the initial tocilizumab dose may be delayed to adhere to the protocol risk mitigation strategy or per the investigator's clinical judgment
  • Prior stem cell transplant at any time
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive tocilizumab until the commercial availability of the drug or up to 5 years, whichever is earlier.

    Drug: Tocilizumab

Interventions

  • 162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly

    Also known as: RoActemra, Actemra

06

What researchers measure

Primary outcomes

  1. Juvenile Arthritis Disease Activity Score (JADAS-71)

    Time frame: Baseline up to 3 years

  2. Percentage of Participants With Adverse Events (AEs), Serious AEs (AEs) and AEs of Special Interest

    Time frame: Baseline up to 5 years

Secondary outcomes

  1. Childhood Health Assessment Questionnaire (CHAQ) Score

    Time frame: Baseline up to 3 years

  2. Percentage of Participants With Protocol Defined Inactive Disease/Clinical Remission

    Time frame: Baseline up to 3 years

07

Study locations

31 sites
  • Arkansas Children's Hospital Research Institute
    Little Rock, Arkansas 72202, United States
  • University of Chicago Hospital
    Chicago, Illinois 60637, United States
  • Hackensack University Medical Center; Pediatric Rheumatology
    Hackensack, New Jersey 07601, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
    Cincinnati, Ohio 45229-3039, United States
  • Cleveland Clinic Fndn
    Cleveland, Ohio 44195, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States
  • University of Utah; Immunology/Rheumatology/Allergy
    Salt Lake City, Utah 84109, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hospital Gral de Niños Pedro Elizalde
    Buenos Aires, C1270AAN, Argentina
  • Hospital de Ninos de la Santisima Trinidad; Hematología
    Cordoba, X5000XAF, Argentina
  • Westmead Hospital; Paediatric Rheumatology
    Westmead, New South Wales 2145, Australia
  • Royal Children'S Hospital; Paediatric Rheumatology
    Parkville, Victoria 3052, Australia
  • Universidade Federal de Sao Paulo - UNIFES
    Sao Paulo, SP 04026-000, Brazil
  • Hospital das Clinicas - FMUSP
    Sao Paulo, SP 05403-900, Brazil
  • Alberta Children'S Hospital
    Calgary, Alberta T3B 6A8, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • CH de Bicêtre; Pediatrie Generale
    Le Kremlin Bicêtre, 94275, France
  • Charité Campus; Virchow Klinikum Berlin
    Berlin, 13353, Germany
  • Uniklinikum Freiburg Zentrum für Kinder- und Jugendmedizin; Pädiatrische Infektio- u. Rheumatologie
    Freiburg, 79106, Germany
  • Asklepios Klinik; Zentrum für Allgemeine Pädiatrie und Neonatologie
    Sankt Augustin, 53757, Germany
  • Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina
    Roma, Lazio 00165, Italy
  • Hospital Infantil de México "Federico Gomez"; Rheumatology
    Mexico, 06720, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria
    Monterrey, 64460, Mexico
  • SI Sceintific children health center RAMS
    Moscow, 119991, Russian Federation
  • Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica
    Esplugas DE Llobregat, Barcelona 08950, Spain
  • Hospital Ramon y Cajal ; Servicio de Reumatologia
    Madrid, 28034, Spain
  • Hospital de La Paz; Unidad de Reumatologia Pediatrica
    Madrid, 28046, Spain
  • Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica
    Valencia, 46026, Spain
  • Bristol Royal Hospital for Children; Rheumatology Department
    Bristol, BS2 8BJ, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, L12 2AP, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Nov 2021, 88 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2014
First posted
Jun 17, 2014
StartActual
Jul 16, 2014
Primary completionActual
Nov 24, 2021
CompletionActual
Nov 24, 2021
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02165345
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 17, 2014
Start date
Jul 16, 2014
Primary completion
Nov 24, 2021
Completion
Nov 24, 2021
Last update
Feb 23, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion